| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000004038 |
| Receipt No. | R000004858 |
| Official scientific title of the study | Study of the neutrophil myelo- peroxidase index (MPXI) with blood disorders, immune disorders or circulatory diseases |
| Date of disclosure of the study information | 2010/08/12 |
| Last modified on | 2017/03/01 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Study of the neutrophil myelo- peroxidase index (MPXI) with blood disorders, immune disorders or circulatory diseases | |
| Title of the study (Brief title) | Study of the neutrophil myelo- peroxidase index (MPXI) with blood disorders, immune disorders or circulatory diseases | |
| Region |
|
|
| Condition | |||||
| Condition | blood, immune disorders and circulatory diseases | ||||
| Classification by specialty |
|
||||
| Classification by malignancy | Malignancy | ||||
| Genomic information | NO | ||||
| Objectives | |
| Narrative objectives1 | A purpose of this study is to determine significance of the neutrophil myeloperoxidase index (MPXI) with blood disorders, immune disorders or circulatory diseases, and to make use of MPXI for early diagnosis and prognostic estimate of these diseases. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1)Correlation between inflammatory marker and MPXI in inflammatory disorder or immune disorder
2)Correlation between morphologic diagnosis using a smear observation and MPXI in leukemia, MDS, or MPO deficiency 3) Correlation between Troponin one or CK-MB and MPXI in ischemic heart disease |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who had a diagnosis of blood disorder, immune disorder or circulatory disease by a biochemical test, an immunologic test and a hematologic test including a smear examination | |||
| Key exclusion criteria | 1)Inappropriate patients for this study judged by the diagnosticians
2)Patients cannot agree to participate in this trial. |
|||
| Target sample size | 300 | |||
| Research contact person | |
| Name of lead principal investigator | Osamu Horie |
| Organization | Kobe University Graduate School of Health Sciences |
| Division name | Division of Medical Biophysics |
| Address | 7-10-2 Tomogaoka, Suma-ku, Kobe City, Hyogo, Japan |
| TEL | 078-796-4558 |
| horie@kobe-u.ac.jp | |
| Public contact | |
| Name of contact person | Kenji Yonezawa |
| Organization | Kobe University Graduate School of Health Sciences |
| Division name | Division of Medical Biophysics |
| Address | 7-10-2 Tomogaoka, Suma-ku, Kobe City, Hyogo, Japan |
| TEL | 078-929-1151 |
| Homepage URL | |
| k.yonezawa717@gmail.com | |
| Sponsor | |
| Institute | Kobe University Graduate School of Health Sciences |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kobe University Graduate School of Health Sciences |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Hyogo Cancer Center |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | We observe the correlation between MPXI and various clinical laboratory data in detail. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004858 |